AD17002
Phase 2Biologic
AD17002 is one of 72 biologic programs targeting Allergic Rhinitis. It is currently in Phase 2.
3
Indications
5
Total Trials
1
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1AD17002
AAdvagene Biopharma Co. Ltd.
Phase 2
Rayaldee
OOrganon and Co
Preclinical
Statins
SanofiPreclinical
Olokizumab
UCBPreclinical
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Pfizer-COVID-19 Vaccine
ModernaPreclinical
Opaganib
RRedHill Biopharma Limited
Preclinical
Covid Infection
KKing's College London
Preclinical
Hymecromone
SStanford University
Preclinical
Saliva Collection
DDirection Centrale du Service de Santé des Armées
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma2 trials
COVID-192 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AD17002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- AAdvagene Biopharma Co. Ltd.